Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Jazz Pharmaceuticals plc - Ordinary Shares (NQ:JAZZ)

171.33 -5.20 (-2.95%)
Streaming Delayed Price Updated: 12:16 PM EST, Dec 1, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Jazz Pharmaceuticals plc - Ordinary Shares

< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
News headline image
Biotech Space Offers Reward In 2023 Despite Economic Risks ↗
Despite the economic headwinds, the mid-to long-term outlook for the biotech space remains strong, and investors who are able to take advantage of undervalued biotech stocks may be well-positioned for... 
Via Talk Markets
News headline image
Struggling Axsome Stock Could Bounce Back on Drug Trial Success
Axsome Pharmaceuticals may be struggling to get out of the red but the success of two very recent drug trials could quickly change all of that. 
Via MarketBeat
News headline image
Q3 Proves To Be Another Tough Quarter For Cannabis ↗
It’s been a tough year for cannabis investors and Q3 offered little relief. 
Via Talk Markets
News headline image
Goldman Sachs, Walmart And These 2 Stocks Insiders Are Selling ↗
The Nasdaq Composite dropped around 0.5% on Friday. Investors, meanwhile, focused on some notable insider trades. 
Via Benzinga
News headline image
Want to Double Your Money? Buying These Stocks Could be a Genius Move ↗
These stocks are undervalued considering their long-term growth potential. 
Via The Motley Fool
News headline image
Is Axsome Therapeutics Stock a Buy Now? ↗
The company seems to be coming into its own. 
Via The Motley Fool
News headline image
Why Shares of Zymeworks Rose 12.18% on Monday ↗
The biotech stock's shares may have been pushed by a short squeeze. 
Via The Motley Fool
News headline image
Why Zymeworks Stock Is Soaring Today ↗
Investors applauded a major licensing deal with Jazz Pharmaceuticals. 
Via The Motley Fool
News headline image
Prediction: This Growth Stock Could Double in 2023 ↗
The next year should be a busy one for this drugmaker. 
Via The Motley Fool
News headline image
Three CBD Stocks to Dominate a Budding Industry
The CBD industry is growing at a high 20% CAGR and is expected to more than triple in size over the next 6 to 7 years, that's a budding opportunity. 
Via MarketBeat
Topics Cannabis
News headline image
Analyst Bumps Up Price Target For Avadel Pharmaceuticals After Favorable Patent Ruling ↗
Last Friday, Delaware District Court granted Avadel Pharmaceuticals plc's (NASDAQ: AVDL) motion to delist the ‘963 Xyrem REMS patent. 
Via Benzinga
News headline image
Avadel Pharmaceuticals Announces Favorable Ruling Regarding Sleep Disorder Drug Patent ↗
 
Via Benzinga
News headline image
Got $500? 3 Growth Stocks to Buy That Could Double Your Money ↗
Innovative products and services could keep these companies growing. 
Via The Motley Fool
News headline image
3 Top Cannabis Stocks to Buy in November ↗
These solid performers are managing to grow revenue in a difficult environment. 
Via The Motley Fool
News headline image
2 Dirt Cheap Growth Stocks to Buy and Hold for Years ↗
In the long run, these stocks could deliver great returns. 
Via The Motley Fool
News headline image
What 5 Analyst Ratings Have To Say About Jazz Pharmaceuticals ↗
Within the last quarter, Jazz Pharmaceuticals (NASDAQ:JAZZ) has observed the following analyst ratings: 
Via Benzinga
News headline image
Jazz Pharmaceuticals Announces Q3 2022 Financial Results, Raises Total Revenue Guidance ↗
Jazz Pharmaceuticals plc (NASDAQ: JAZZ) announced its financial results late Wednesday for the third quarter of 2022 and raised the mid-point of 2022 total revenue guidance. 
Via Benzinga
News headline image
Why Axsome Therapeutics Stock Slipped Today ↗
Investors traded out of the company following the latest earnings release, but only to a modest degree. 
Via The Motley Fool
News headline image
3 Top Healthcare Stocks to Buy for November ↗
Catalysts lie ahead for these promising stocks. 
Via The Motley Fool
News headline image
2 Marijuana Stocks That Are Set for a Comeback ↗
Don't overlook these top stocks when investing in the marijuana space. 
Via The Motley Fool
News headline image
Jazz Pharma's Zepzelca For Lung Cancer Flunked Confirmatory Trial, But FDA Will Not Pull Accelerated Approval ↗
A petition was filed requesting that the FDA initiate proceedings to withdraw approval of all medications containing lurbinectedin, currently marketed under the brand Zepzelca by Jazz Pharmaceuticals... 
Via Benzinga
News headline image
Analyst Moves To Sidelines After Jazz Pharma Deal Shifts Zymeworks To Early Stage Pipeline ↗
 
Via Benzinga
News headline image
Why Is Zymeworks (ZYME) Stock Up Today? ↗
Zymeworks (ZYME) stock is climbing higher on Wednesday after the company signed a licensing agreement with Jazz Pharmaceuticals (JAZZ). 
Via InvestorPlace
News headline image
Jazz Obtains Exclusive Rights To Zymeworks' Cancer Candidate In Almost $2B Biobuck Deal ↗
 
Via Benzinga
News headline image
10 Health Care Stocks Whale Activity In Today's Session ↗
This whale alert can help traders discover the next big trading opportunities. Whales are entities with large sums of money and we track their transactions here at Benzinga on our options activity... 
Via Benzinga
News headline image
2 Biotech Stocks You Can Buy and Hold for the Next Decade ↗
These two durable companies can navigate the market downturn and beyond. 
Via The Motley Fool
News headline image
3 Red-Hot Stocks That Could Continue to Beat the Market ↗
Investors are betting on these companies' revenue growth prospects. 
Via The Motley Fool
News headline image
3 Top Marijuana Stocks to Buy for the Long Haul ↗
The three have the financial strength to benefit from increased cannabis sales and cannabis therapies. 
Via The Motley Fool
News headline image
3 Stocks Savvy Investors Are Buying Hand Over Fist ↗
These high-flying stocks are defying the bear market. 
Via The Motley Fool
News headline image
Japan Is Inching Toward Cannabis Legalization, Companies Like This One Could Benefit ↗
A Japanese health ministry panel recommended that marijuana-derived medicines be treated the same as pharmaceuticals, reported Bloomberg. The expert panel, convened on Thursday, recommended a revision... 
Via Benzinga
< Previous 1 2
...
9 10 11 12 13 14 15 16 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.